We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

28 hedge funds and large institutions have $5.72M invested in Lexaria Bioscience in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

77% more capital invested

Capital invested by funds: $3.23M → $5.72M (+$2.49M)

12% more funds holding

Funds holding: 25 → 28 (+3)

7.36% more ownership

Funds ownership: 7.01% → 14.37% (+7.4%)

Holders
28
Holders Change
+3
Holders Change %
+12%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
10
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$3.06M
2
G
GenTrust
Florida
+$180K
3
ICM
Invenomic Capital Management
Massachusetts
+$121K
4
BlackRock
BlackRock
New York
+$77.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$68.4K

Top Sellers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
-$77K
2
Citadel Advisors
Citadel Advisors
Florida
-$57.6K
3
Morgan Stanley
Morgan Stanley
New York
-$1.12K
4
Bank of America
Bank of America
North Carolina
-$423
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.84M +$3.06M +1,020,000 New
ICM
2
Invenomic Capital Management
Massachusetts
$1.43M +$121K +40,308 +9%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$319K +$46.3K +15,445 +16%
Vanguard Group
4
Vanguard Group
Pennsylvania
$260K +$25.3K +8,430 +10%
G
5
GenTrust
Florida
$167K +$180K +60,000 New
RJFSA
6
Raymond James Financial Services Advisors
Florida
$136K +$27.7K +9,250 +23%
State Street
7
State Street
Massachusetts
$109K – – –
BlackRock
8
BlackRock
New York
$76.3K +$77.8K +25,937 +1,720%
WG
9
Welch Group
Alabama
$66.7K – – –
Morgan Stanley
10
Morgan Stanley
New York
$63.9K -$1.12K -372 -2%
Renaissance Technologies
11
Renaissance Technologies
New York
$63.4K +$68.4K +22,800 New
Northern Trust
12
Northern Trust
Illinois
$51.1K – – –
Wealth Enhancement Advisory Services
13
Wealth Enhancement Advisory Services
Minnesota
$38.4K +$10.5K +3,500 +34%
XT
14
XTX Topco
Cayman Islands
$35K +$6.98K +2,326 +23%
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$20K – – –
OC
16
Oakworth Capital
Alabama
$13.9K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$9.37K +$2K +668 +25%
Wells Fargo
18
Wells Fargo
California
$9.17K +$6.68K +2,227 +208%
1832 Asset Management
19
1832 Asset Management
Ontario, Canada
$7.47K – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$6.37K +$300 +100 +5%
ACM
21
ADAR1 Capital Management
Texas
$2.63K -$77K -25,681 -96%
APC
22
Aspire Private Capital
North Carolina
$1.11K – – –
FFA
23
Farther Finance Advisors
California
$458 – – –
MG
24
Mather Group
Illinois
$363 +$300 +100 New
Bank of America
25
Bank of America
North Carolina
$267 -$423 -141 -59%
1
2

LEXX Hedge Fund Activity: Q2 2024 in Review

28 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2024, worth a combined $5.72M — up 77% from $3.23M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new LEXX positions and 1 closed out — a net gain of 3 holders — while 10 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.06M. The largest seller was ADAR1 Capital Management, cutting an estimated $77K.

  • 28 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2024, up from 25 in Q1 2024.
  • Funds reported $5.72M of Lexaria Bioscience stock for Q2 2024, up 77% quarter-over-quarter.
  • 4 funds opened new Lexaria Bioscience positions in Q2 2024 and 1 closed out, a net change of +3 holders.
  • The largest Lexaria Bioscience buyer in Q2 2024 was Armistice Capital, an estimated $3.06M added.
  • The largest Lexaria Bioscience seller in Q2 2024 was ADAR1 Capital Management, an estimated $77K sold.

Based on aggregated 13F filings for Q2 2024.